Department of Medicine
Faculty Profiles by Division

Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine

Faculty Profiles

[Return To Index page]
photo Anuradha Ray, PhD

Pulmonary, Allergy and Critical Care Medicine

Professor of Medicine and Immunology

UPMC Endowed Chair in Lung Immunology

Email: raya@pitt.edu

Phone: 412-692-2118

Contact
Office: UPMC Montefiore Hospital, NW628
3459 Fifth Avenue
Pittsburgh, PA 15213
 
Phone: 412-692-2118
Fax: 412-692-2260
E-mail: raya@pitt.edu
Administrative Assistant:
Patty Geraci
Email: geracip@upmc.edu
Phone: 412-692-2118
Fax: 412-692-2260
Education and Training
Education
B.Sc., Chemistry, Calcutta University, 1976
M.Sc., Biochemistry, Calcutta University, 1978
PhD, Molecular Biology, Calcutta University, 1984
Postdoctoral Fellowship, Cornell University, 1986
Training
Postdoctoral Fellowship, Cornell University, 1987
Postdoctoral Associate, The Rockefeller University, 1988
Research Interest
Dr. Ray’s overall research interest is to understand mechanisms of immune tolerance versus inflammation in the lung as they relate to pulmonary diseases such as severe asthma and host-pathogen interactions. Early research from her lab led to the identification of NF-?B as a target for glucocorticoid-mediated repression of gene expression and the discovery of GATA-3 as a master regulator of Th2 cells, which promote allergic diseases including asthma. Her laboratory also identified a key role for Tregs expressing membrane-bound TGF-ß with cross-talk with Notch in promoting immune tolerance in the airways.

The primary goal of Dr. Ray’s current research is to understand the immunological and molecular differences between severe and milder asthma and the mechanisms underlying poor response to corticosteroids in severe disease. A study published recently by her group has demonstrated an
IFN-?/Th1 immune bias in more than 50% of severe asthmatics. This study also utilized a newly developed animal model of severe asthma established in her lab, which can be used to test novel therapeutics for severe asthma. This bedside-bench study identified a detrimental role of IFN-? in downregulating expression of the protease inhibitor, SLPI, in the airways of both humans and mice. In the context of immune tolerance, her recently published study has identified an important role of mitochondrial metabolism in lung dendritic cells in the maintenance of immune tolerance in the airways. Studies in her laboratory employ animal models of disease and human samples, which are analyzed using immunological, molecular, biochemical, physiological and imaging techniques.
Publications
For my complete bibliography, Click Here.
Selected Publications:
Khare, A., Raundhal, M., Chakraborty, K., Das, S., Corey, C., Kamga, C.K., Quesnelle, K., St. Croix, C., Watkins, S.C., Morse, C., Oriss, T.B., Huff, R., Hannum, R., Ray, P., Shiva, S., Ray, A. Mitochondrial H2O2 in lung antigen-presenting cells blocks NF-kappaB activation to block unwarranted immune activation. Cell Reports. 2016; 15: 1700-1714.
Ray, A., Prefontaine, K.E. Physical association and functional antagonism between the p65 subunit of NF-kappaB and the glucocorticoid receptor. Proceedings of the National Academic Science of the United States of America. 1994; 91: 752-756.
Zang, D.-H,, Cohn, L., Ray, P, Bottomly, K., Ray, A. Transcription factor GATA-3 is differentially expressed in Th1 and Th2 cells and controls Th2-specific expression of the interleukin-5 gene. Journal of Biological Chemistry. 1997; 272: 21597-21603.
Zhang, D.-H., Yang, L., Cohn, L., Parkyn, L., Homer, R., Ray, P., Ray, A. Inhibition of allergic inflammation in a murine model of asthma by expression of a dominant-negative mutant of GATA-3. Immunity. 1999; 11: 473-482.
Das, J., Chen, C.-H, Yang, L., Cohn, L., Ray, P., Ray, A. A critical role of NF-kappaB in GATA-3 gene expression and Th2 differentiation in allergic airway inflammation. Nature Immunology. 2001; 2: 45-50.
Ostroukhova, M., Sequin-Devaux, C., Oriss, T.B., Dixon-McCarthy, B., Yang, L., Ameredes, B., Corcoran, T.E., Rray, A. Tolerance Induced by Inhaled Antigen Involves CD4+ T Cells Expressing Membrane-Bound TGF-Beta and FOXP3. Journal of Clinical Investigation. 2004; 114: 28-38.
Ostroukhova, M., Qi, Z., Oriss, T.B., Dixon-McCarthy, B., Ray, P., Ray, A. T Regulatory Cell-Mediated Immunosuppression Involves Activation of the Notch-HESI Axis By Membrane-bound TGF-Beta. Journal of Clinical Investigation. 2006; 116: 996-1004.
Fei, M., Bhatia, S., Oriss, T.B., Yarlagadda, M., Khare, A., Akira, S., Saijo, S,, Iwakura, Y., Fallert-Junecko, B.A., Reinhart, T., Foreman, O., Ray, P., Kolls, J,K., Ray, A. TNF-alpha From Inflammatory DCs Regulates Lung IL-17A/IL-5 Levels and Neutrophilia Versus Eosinophilia during Persistent Fungal Infection. Proceedings of the National Academy of Science in the United States of America. 2011; 108: 5360-5365.
Krishnamoorthy, N., Khare, A., Ooriss, T.B., Raundhal, M., Morse, C., Yarlagadda, M., Wenzel, S.E., Moore, M.L., Peebles, R. S., Ray, A., Ray, P. Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma. Nature Medicine. 2012; 18: 1525-1530.
Raundhaal, M., Morsse, M., Khare, A., Oriss, T.B., Milosevic, J., Trudeau, J., Huff, R., Pilewski, J., Holguin, F., Kolls, J., Wensel, S.E., Ray, P., Ray, A. High IFN-? and Low SLPI Mark Severe Asthma In Humans and Mice. Journal of Clinical Investigation. 2015; 125: 3037-050.
Sponsored Research/Activities
Title: Understanding Severe Asthma Using an Experimental Model
Role: Principal Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL113956
Start Year: 2018
End Year: 2022
Title: Mechanisms of Antigen-Induced Tolerance in the Lung
Role: Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: R01 AI048927
Start Year: 2016
End Year: 2021
Title: Immune Airway-Epithelial Interactions in Steroid-Refractory Severe Asthma
Role: Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: P01 AI106684
Start Year: 2015
End Year: 2020
Title: Mining of a comprehensive, proprietary asthma patient data set for new target identification
Role: Co-Principal Investigator
Funding Agency: Pieris Pharmaceuticals, Inc.
Grant Number: RES
Start Year: 2019
End Year: 2023
Title: Protein-Oxidized Phospholipid Interactions Determine Epithelial Cell Fate and Asthma Control
Role: Co-Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: R01 AI45406
Start Year: 2020
End Year: 2024
Notable Achievements
Member -Lung Biology and Pathology (LBPA) Study Section, 1999-2003
Elected member of Faculty of 1000 Biology in Immunology Discipline, 2004
Appointed Member of University Research Council,, 2006-2009
Associate Editor, Mucosal Immunology, 2010-
Member “Board of Scientific Counselors” to review NIAID Intramural Programs in Immunology, 2012
Member, NIH LCMI study section, 2012-2016
Joseph S. Ingraham Immunology Lecturer for 2013, The Department of Microbiology and Immunology at Indiana University School of Medicine, 2013
Invited by Merck & Co., Inc. as Immunology training lecturer in preparation for launching of their new immunotherapy initiative, 2013
Associate Editor, American Journal of Respiratory, Cell and Molecular Biology, 2013
American Thoracic Society’s Recognition Award for Scientific Accomplishments, 2016